Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Other Non Operating Income (2017 - 2025)

Marimed has reported Other Non Operating Income over the past 10 years, most recently at -$753000.0 for Q4 2025.

  • Quarterly Other Non Operating Income changed N/A to -$753000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$717000.0 through Dec 2025, down 1334.0% year-over-year, with the annual reading at -$717000.0 for FY2025, 1334.0% down from the prior year.
  • Other Non Operating Income was -$753000.0 for Q4 2025 at Marimed, down from $19000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.0 million in Q1 2022 and troughed at -$900000.0 in Q1 2023.
  • The 5-year median for Other Non Operating Income is -$30000.0 (2024), against an average of -$188352.9.
  • Year-over-year, Other Non Operating Income skyrocketed 100300.0% in 2022 and then tumbled 229.17% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$737000.0 in 2021, then skyrocketed by 96.74% to -$24000.0 in 2022, then tumbled by 229.17% to -$79000.0 in 2023, then soared by 62.03% to -$30000.0 in 2024, then crashed by 2410.0% to -$753000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Other Non Operating Income are -$753000.0 (Q4 2025), $19000.0 (Q3 2025), and $17000.0 (Q2 2025).